Diuretics for Chronic Kidney Disease

Recruiting in Palo Alto (17 mi)

+1 other location

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Stanford University

Prior Safety Data

Approved in 3 Jurisdictions

Trial Summary

What is the purpose of this trial?

This study will determine the efficacy of diuretics in patients with chronic kidney disease.

Research Team

Eligibility Criteria

This trial is for stable chronic kidney disease patients who can consent, including those on dialysis but still producing urine. It's not for those recently hospitalized or with unstable food intake, nor for anyone using antibiotics in the last two months or expecting to use them.

Inclusion Criteria

I am on stable dialysis, can still urinate, and can give consent.

I have stable kidney disease and can give my consent.

Exclusion Criteria

You have recently been in the hospital or had an event that made it hard for you to eat regularly.

I have used antibiotics in the last two months or expect to use them.

Treatment Details

Interventions

Metolazone (Diuretic)
Placebo (Drug)

Trial OverviewThe study tests the effectiveness of a diuretic called Metolazone compared to a placebo in managing chronic kidney disease. Participants will be randomly assigned to receive either the medication or an inactive substance.

Participant Groups

2Treatment groups

Active Control

Placebo Group

Group I: Metolazone then placeboActive Control1 Intervention

Metolazone will be taken orally during the first week, followed by washout of 1-2 weeks, then placebo will be taken the following week.

Group II: Placebo then MetolazonePlacebo Group1 Intervention

Placebo will be taken orally during the first week, followed by washout of 1-2 weeks, then metolazone will be taken the following week.

Metolazone is already approved in Canada for the following indications: